TY - JOUR
T1 - Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study
T2 - An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
AU - Hørslev-Petersen, Kim
AU - Hetland, Merete Lund
AU - Junker, Peter
AU - Pødenphant, Jan
AU - Ellingsen, Torkell
AU - Ahlquist, Palle
AU - Lindegaard, Hanne
AU - Linauskas, Asta
AU - Schlemmer, Annette
AU - Dam, Mette Yde
AU - Hansen, Ib
AU - Horn, Hans Christian
AU - Ammitzbøll, Christian Gytz
AU - Jørgensen, Anette
AU - Krintel, Sophine B
AU - Raun, Johnny
AU - Johansen, Julia S
AU - Ostergaard, Mikkel
AU - Stengaard-Pedersen, Kristian
AU - OPERA study-group
PY - 2014
Y1 - 2014
N2 - OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP
AB - OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP
U2 - 10.1136/annrheumdis-2012-202735
DO - 10.1136/annrheumdis-2012-202735
M3 - Journal article
C2 - 23434570
SN - 0003-4967
VL - 73
SP - 654
EP - 661
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 4
ER -